K-ras mutations and cetuximab in colorectal cancer [9]

New England Journal of Medicine

Volumn 360, Issue 8, 2009, Pages 835-

  Gattenlohner, Stefan ^a   Germer, Christoph ^a   Muller Hermelink, Hans Konrad ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLORECTAL TUMOR; GENETICS; HUMAN; METASTASIS; MUTATION; NOTE; ONCOGENE RAS; PATHOLOGY;

COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; MUTATION; NEOPLASM METASTASIS;

EID: 61449218024     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for a European quality assurance program. Virchows Arch 2008;453:417-31.
2. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26:4217-9.
3. Tórtola S, Steinert R, Hantschick M, et al. Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol 2001;19: 2837-43. (Pubitemid 32538192)